Pierwotne stwardniające zapalenia przewodów żółciowych – znaczenie czynników żywieniowych

• Authors: Wróblewska Edyta , Tyszko Piotr , Okręglicka Katarzyna
• Languages of publication: PL

Keywords

PL

pierwotne stwardniające zapalenie przewodów żółciowych; wapń; witaminy; probiotyki; alkohol

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2014
• Issue: 4
• Pages: 378-381

Contributors

author

Wróblewska Edyta

author

Tyszko Piotr

author

Okręglicka Katarzyna

References

• Menon Narayanan KV, Weisner RU. Etiology and natural history of primary sclerosing cholangitis. J Hepatobil Pancr Surg 1999; 6: 343–351.
• Brome U, Berquist A. Primary sclerosing cholangitis. In: Boyer T, Wright T, Manns M, eds. Zakim and Boyer’s hepatology.Saunders, Elsevier; 2006: 821–854.
• Worthington J, Chapman R. Primary sclerosing cholangitis. Orphanet J Rare Dis 2006; 1: 41.
• Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004; 126: 1929–1930.
• Lazaridis KN . Sclerosing cholangitis epidemiology and etiology. J Gastrointest Surg 2008; 12: 417–419.
• Al-Osaimi A, Berg C. Association of primary sclerosing cholangitis and celiac disease: a case report and review of the literature.Dig Dis Sci 2004; 49: 438–443.
• Talwalkar JA, Lindor KD . Primary sclerosing cholangitis. Inflamm Bowel Dis 2005; 11: 62–72.
• Younossi Z, Kiwi ML, Boparai N, et al. Cholestatic liver diseases and health – related quality of life. Am J Gastroenterol 2000;95: 497–502.
• Hay JE, Lindor KD , Weisner RH, et al. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 1991; 14:257–261.
• Angulo P, Therneau TM, Jorgenson RA , et al. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol 1998; 29: 729–735.
• Lin CL , Moniz C, Chambes TJ, et al. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology 1996; 111: 1263–1271.
• Lukert BP, Raisz LG . Glucocorticoid – induced osteoporosis pathogenesis and management. Ann Intern Med 1990; 112:352–364.
• Porayko MK, Weisner RH, Hay JE, et al. Bone disease in liver transplant recipients: incidence, timing, and risk factors. Transplant Proc 1991; 23: 1462–1465.
• Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primarzsclerosing cholangitis. J Hepatol 2002;36: 321–327.
• Guglielmi FW, Panella C, Buda A, et al. Nutritional state and energy balance in cirrhotic patients with or without hypermetabolism.Multicentre prospective study on the nutritional problems in Gastroenterology Section by the Italian Society of Gastroenterology (SIG E). Dig Liver Dis 2005; 37: 681–688
• Maillette de Buy Wenniger L, Beuers U. Bile salts and cholestasis. Dig Liver Dis 2010; 42: 409– 418.
• Rost D, Kulaksiz H, Stiehl A. Treatment of primary sclerosing cholangitis. Curr Treat Options Gastroenterol 2007; 10: 111–119.
• Levy C, Lindor KD . Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis. Curr Treat Options Gastroenterol 2003; 6(2): 93–103.
• Angulo P, Grandison GA , Fong DG , et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011;140(1): 180–188.
• Floreani A, Baragiotta A, Martines D, et al. Plasma antioxidant levels in chronic cholestatic liver diseases. Aliment Pharmacol Ther 2000; 14(3): 353–358.
• Grant AJ, Lalor PF, Hubscher SG , et al. MAdCA M-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCA M-1 in chronic inflammatory liver disease). Hepatology 2001; 33: 1065–1072.
• Davies YK , Cox KM, Abdullah BA , et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin:an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008; 47: 61–67.
• Isaacs K, Herfarth H. Role of probiotic therapy in IBD . Inflamm Bowel Dis 2008; 14: 1597–1605.
• Vleggaar FP, Monkelbaan JF, Van Erpecum KJ. Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol 2008; 20: 688–692.
• Hagström H, Stål P, Stokkeland K, et al. Alcohol consumption in patients with primary sclerosing cholangitis. World J Gastroenterol 2012; 18(24): 3105–3111.
• Corrao G, Bagnardi V, Zambon A, et al. Meta-analysis of alcohol intake in relation to risk of liver cirrhosis. Alcohol Alcohol 1998; 33: 381–392.
• Ekstedt M, Franzén LE, Holmqvist M, et al. Alcohol consumption is associated with progression of hepatic fibrosis in nonalcoholic fatty liver disease. Scand J Gastroenterol 2009; 44: 366–374.
• Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter casecontrol study. Hepatology 2000; 31: 7–11.
• Kamper-Jørgensen M, Grønbaek M, Tolstrup J, et al. Alcohol and cirrhosis: dose-response or threshold effect? J Hepatol 2004;41: 25–30.
• Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41: 845–850.
• Sjoberg K, Lindgreen S, Eriksson S. Frequent occurrence of non – specyfic gliadin antibodies in chronic cholestatic liver disease.Endomysial but not gliadin antibodies predict celiac disease in patients with chronic liver disease. Scand J Gastroenterol 1997; 32: 1162–1167.
• Satora D, Bochen K, Prystupa A, et al. Celiakia – choroba nie tylko dziecięca. Fam Med Prim Care Rev 2011; 13(1): 90–94.
• Størsrud S, Malmheden Yman I, Lenner RA . Gluten contamination in oat products and products naturally free from gluten. EurFood Res Technol 2003; 217: 481–485.
• Tysk C. Concurent ulcerative colitis, celiac sprue, and primary sclerosing cholangitis. J Clin Gastroenterol 1994; 18: 421–422.
• Schrumpf E, Abdelnoor M, Fausa O, et al. Risk factors in primary sclerosing cholangirtis. J Hepatol 1994; 21: 1061–1066.
• Volta U, Rodrigo L, Alessandro G, et al. Celiac disease in autoimmune cholestatic liver disorders. Amer. J Gastroenterol 2002;97(10): 2609–2613.